Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93

Gilead Sciences Announces Third Quarter 2016 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared a cash dividend of $0.47 per share of common stock for the third quarter of 2016. The dividend is payable on September 29, 2016,... More

Gilead Sciences Announces Second Quarter 2016 Financial Results

- Product Sales of $7.7 billion -

- Diluted EPS of $2.58 per share -

- Non-GAAP Diluted EPS of $3.08 per share -

- Revised Full Year 2016 Guidance -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016. The financial results that follow represent a year-over-year comparison of second quarter 2016 to the second quarter 2015. Total revenues were $7.8 billion in 2016 compared to $8.2 billion in 2015.... More

European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

If Approved, Truvada for PrEP in Combination with Safer Sex Practices Could Offer Uninfected Adults at High Risk a New Option to Reduce the Risk of Acquiring HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the companys Type II variation application for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 mg) in combination with safer sex practices to reduce the... More